Branded Legacy Leadership Team Resigns Ahead of Planned Merger

*ORLANDO, Fla.* — David Oswald, Philip White, and the rest of the existing
management team at Branded Legacy Inc. resigned ahead of a strategic merger
aimed at positioning the company for growth in the burgeoning addiction
therapeutics sector. Branded Legacy Inc. (OTC: BLEG) is a diversified
holding company focused on plant-based functional wellness and the rapidly
expanding cannabis beverage sector.

Jeffery Robison has been appointed Interim CEO to guide the company through
this transitional period. In his role, Mr. Robison is leading negotiations
for a major merger with an innovative addiction therapeutics company. A
Letter of Intent (LOI) has been submitted and is expected to be executed
this week, with full execution anticipated by week’s end. The merger is
projected to close within the next two weeks, subject to final agreements
and regulatory approvals.

Addictions represent a globally increasing health crisis, with current
treatments often proving ineffective, expensive, and inaccessible to many
patients. The target company has developed advanced technology and
assembled leading experts to address this challenge, with a focus on
Naloxone, which is leading the intranasal device market for opioid overdose
reversal.

The target company is revolutionizing intranasal drug delivery by
redesigning naloxone administration as an all-in-one device that reduces
costs while overcoming limitations of existing market products. Their
patented all-in-one device simplifies what is currently a complex,
multi-part system, thereby lowering operational complexity and enhancing
dose precision for improved treatment consistency, simplified prescribing,
and easier usage.

Beyond naloxone, the target company’s innovative platform enables nasal
administration of compounds that conventional intranasal devices cannot
reliably deliver due to physical, chemical, or manufacturing constraints,
opening up new treatment options. A second device invention allows for
mixing solutions with lyophilized powder, expanding into additional markets
such as vaccines and other medications that were previously inaccessible.
This intranasal delivery approach facilitates quicker pandemic responses,
enables self-use vaccination, and supports underserved, hard-to-reach
regions globally. For many medications requiring continuous
refrigeration—the “cold chain”—this point-of-care reconstitution capability
significantly streamlines delivery logistics.

As part of its strategy, the target company is targeting other cold
chain-dependent medications to further broaden its impact in global health
solutions.

This merger will integrate a highly accomplished and reputable management
team with extensive expertise in addiction therapeutics and advanced
medicine delivery systems. Key members include a professor holding a PhD,
renowned for expertise in health research methods, evidence synthesis, and
impact, who has led groundbreaking clinical trials, including high-profile
studies on drug effectiveness for COVID-19 and preventive therapeutics,
contributing to global health advancements with a focus on rigorous
evidence-based medicine; a biostatistician and doctor, a serial
entrepreneur with over 15 years in data science and AI, who has founded
multiple health technology companies leading to successful exits,
specializing in innovative clinical trial designs, Bayesian statistics,
meta-analysis, and complex evidence synthesis; and the President & CEO, a
pharmacist and clinical research coordinator with a strong background in
pharmaceutical sciences, clinical development, and coordinating research
efforts to advance therapeutic solutions.

The incoming team’s innovations emphasize cost-effective solutions that
enhance accessibility and efficiency in treatment delivery, aligning with
Branded Legacy’s vision for transformative growth. The combined entity
projects revenue of $40 million in its first year, driven by these
cutting-edge technologies and market expansions.

“The addiction therapeutics industry represents a dynamic and rapidly
expanding market, poised for substantial advancement,” said Robison.
“According to recent industry reports, the global addiction treatment
market was valued at approximately $9 billion in 2023 and is projected to
reach over $16.7 billion by 2033, growing at a compound annual growth rate
(CAGR) of around 6.6%. Additionally, the global naloxone market was valued
at approximately $1.07 billion in 2023 and is expected to reach $2.48
billion by 2032. This growth is driven by the rising prevalence of opioid
addictions, advancements in reversal therapies, and innovations in
intranasal delivery systems that reduce costs and improve patient outcomes.
Our merger positions Branded Legacy to capitalize on these opportunities,
bringing innovative, affordable solutions to patients worldwide.”

The merger is expected to diversify Branded Legacy’s portfolio, leveraging
the new team’s proven track record in developing therapies that address
unmet needs in addiction treatment while emphasizing cost-efficiency.

Branded Legacy Inc. remains committed to transparency and will provide
updates as the merger progresses. Investors and stakeholders are encouraged
to monitor the company’s filings for further details.